Compare BCBP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | CRVS |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 1.2B |
| IPO Year | 2005 | 2016 |
| Metric | BCBP | CRVS |
|---|---|---|
| Price | $10.02 | $15.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $10.00 | ★ $30.17 |
| AVG Volume (30 Days) | 90.3K | ★ 1.1M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $3.17 |
| 52 Week High | $10.25 | $26.95 |
| Indicator | BCBP | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 72.69 | 50.71 |
| Support Level | $7.55 | $14.38 |
| Resistance Level | N/A | $18.73 |
| Average True Range (ATR) | 0.30 | 1.12 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 80.17 | 28.20 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.